Search Results - "Gettinger S"

Psychological Testing of Recruits Can - A) Screen Out the Real Turkeys, B) Spot the Supercops, C) Both of the Above, D) Neither of the Above.

Authors: Gettinger, S. (AUTHOR)

Source: Police Magazine. Mar1981, Vol. 4 Issue 2, p29-40. 7p.

Police and Gun Control - Can the Law Reduce Bloodshed?

Authors: Gettinger, S. (AUTHOR)

Source: Police Magazine. Nov1980, Vol. 3 Issue 6, p6-18. 13p.

SHADOWY WORLD OF RALPH THORSON, BOUNTY HUNTER.

Authors: GETTINGER, S. Criminal Justice Publications, Inc

Source: Police Magazine. May1980, Vol. 3 Issue 3, p51-56. 6p.

PROFILE - BIRMINGHAM.

Authors: GETTINGER, S. Correctional Information Service, Inc

Source: Police Magazine. SUMMER 1977, p27-44. 18p.

Prison Population Boom - Still No End in Sight.

Authors: Gettinger, S. (AUTHOR)

Source: Corrections Magazine. Jun1983, Vol. 9 Issue 3, p6-49. 9p.

Washington State Seeks a Return to Normalcy.

Authors: Ramsey, B. Gettinger, S.

Source: Corrections Magazine. Jun1981, Vol. 7 Issue 3, p33-37. 5p.

PRISON MEDIA - GETTING THE NEWS INSIDE.

Authors: GETTINGER, S. Correctional Information Service, Inc

Source: Corrections Magazine. Mar1976, Vol. 2 Issue 3, p37-44. 8p.

PROFILE/THE ADULT CORRECTIONS SYSTEM IN NEW YORK CITY.

Authors: GETTINGER, S. Correctional Information Service, Inc

Source: Corrections Magazine. Jun1976, Vol. 2 Issue 4, p30-50. 17p.

PROFILE/JUVENILE JUSTICE IN NEW YORK CITY.

Authors: GETTINGER, S. Correctional Information Service, Inc

Source: Corrections Magazine. Jun1976, Vol. 2 Issue 4, p51-57. 7p.

US PRISON POPULATION HITS ALL-TIME HIGH.

Authors: GETTINGER, S. Correctional Information Service, Inc

Source: Corrections Magazine. Mar1976, Vol. 2 Issue 3, p9-20. 10p.

PROFILE/VERMONT.

Authors: GETTINGER, S. Correctional Information Service, Inc

Source: Corrections Magazine. Sep/Oct1975, Vol. 2 Issue 1, p33-50. 18p.

TALK WITH AUTHOR CHARLES SILBERMAN.

Authors: GETTINGER, S. Criminal Justice Publications, Inc

Source: Corrections Magazine. Mar1979, Vol. 5 Issue 1, p29-31. 3p.

1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC.

Authors: Gettinger, S Beck, T Yang, X et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer.

Authors: Gettinger, S. Chow, L.Q. Borghaei, H. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Nov2014 Supplement, Vol. 90 Issue 5, pS34-S35. 1p.

Subjects: Erlotinib, Medication safety, Epidermal growth factor receptors, Lung cancer treatment, Metastasis, Genetic mutation

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer.

Authors: Antonia, S.J. Gettinger, S. Goldman, J. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Nov2014 Supplement, Vol. 90 Issue 5, pS32-S33. 1p.

Subjects: Drug efficacy, Medication safety, Lung cancer treatment, Metastasis, Ipilimumab, Monoclonal antibodies

Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E): Metastatic Non-Small Cell Lung Cancer.

Authors: Horn, L. Gettinger, S. Camidge, R. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Nov2014 Supplement, Vol. 90 Issue 5, pS39-S40. 1p.

Subjects: Cetuximab, Gefitinib, Lung cancer treatment, Metastasis, Skin inflammation, Medical statistics

Bush success on House votes heads for a record low.

Authors: Gettinger, S.

Source: Congressional Quarterly Weekly Report. 10/13/90, Vol. 48 Issue 41, p3387. 1p. 1 Black and White Photograph, 1 Chart.

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆.

Authors: Spigel, D.R. Vicente, D. Ciuleanu, T.E. et al.

Source: Annals of Oncology. May2021, Vol. 32 Issue 5, p631-641. 11p.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.

Authors: Vokes, E E Ready, N Felip, E et al.

Source: Annals of Oncology. Apr2018, Vol. 29 Issue 4, p959-965. 7p. 2 Charts, 2 Graphs.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Borghaei, H. Paz-Ares, L. Horn, L. et al.

Source: New England Journal of Medicine. 10/22/2015, Vol. 373 Issue 17, p1627-1639. 13p.